초록
Green and dark teas are rich in bioactive compounds with potential therapeutic effects in the management of type 2 diabetes mellitus (T2DM). This study aimed to comprehensively evaluate the antidiabetic potential of green and dark teas through an integrated experimental and computational workflow, incorporating metabolomics, enzyme inhibition assays, antioxidant assays, liver cell-based assays, and molecular modelling. A total of 24 commercially available tea samples, green, dark, black, matcha, and rooibos were sourced, and these teas were subjected to untargeted liquid chromatography-mass spectrometry (LC/MS) based metabolomics in negative ion mode to characterise their chemical compositions. Matcha tea served as a positive control due to its well-documented bioactivity, while rooibos served as a negative control since it is derived from a botanically unrelated plant. Black tea was included to differentiate metabolites arising from microbial fermentation in dark tea versus those generated via enzyme oxidation found in black tea. Metabolomic profiling revealed that green and dark teas share a core set of polyphenolic compounds, including epigallocatechin gallate (EGCG), epicatechin gallate (ECG), and gallic acid. Each tea exhibited unique signatures linked to fermentation and processing. Dark teas also contained additional fermentation-related metabolites such as ellagic acid derivatives and esculetin. Enzyme inhibition assays showed that green tea exhibited the strongest inhibition of both α-glucosidase (IC₅₀ = 20.09 ± 3.22 µg/mL) and α-amylase (IC₅₀ = 1.59 ± 0.11 mg/mL), showing significantly greater activity than the other teas (α < 0.001). Matcha and black teas displayed moderate inhibition (α > 0.05 between them), while dark tea showed weaker activity (IC₅₀ =…
초록이 줄여졌습니다. 출처에서 초록 전문 읽기.
초록 텍스트는 PubMed, OpenAlex 또는 Europe PMC에서 가져온 것이며 저자와 출판사에 귀속됩니다.